Somewhat Favorable News Coverage Somewhat Unlikely to Impact Xencor (XNCR) Share Price

Press coverage about Xencor (NASDAQ:XNCR) has been trending somewhat positive on Saturday, Accern Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Xencor earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.6494819494759 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Several research firms recently issued reports on XNCR. BidaskClub upgraded shares of Xencor from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 24th. Zacks Investment Research restated a “sell” rating on shares of Xencor in a research report on Saturday, January 13th. Piper Jaffray Companies restated a “buy” rating and set a $35.00 price objective on shares of Xencor in a research report on Sunday, November 12th. ValuEngine cut shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. Finally, Canaccord Genuity set a $36.00 price objective on shares of Xencor and gave the stock a “buy” rating in a research report on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Xencor presently has a consensus rating of “Hold” and a consensus price target of $30.80.

Shares of Xencor (NASDAQ XNCR) traded down $0.01 during mid-day trading on Friday, reaching $21.70. 167,875 shares of the company’s stock traded hands, compared to its average volume of 161,056. The stock has a market capitalization of $1,019.52, a price-to-earnings ratio of -21.70 and a beta of 1.97. Xencor has a one year low of $18.55 and a one year high of $28.64.

Xencor (NASDAQ:XNCR) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.04). Xencor had a negative return on equity of 15.26% and a negative net margin of 148.29%. sell-side analysts expect that Xencor will post -1.1 EPS for the current fiscal year.

In related news, major shareholder John S. Stafford III bought 5,349 shares of the stock in a transaction on Friday, November 24th. The stock was bought at an average price of $19.85 per share, with a total value of $106,177.65. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder John S. Stafford III acquired 9,215 shares of the stock in a transaction dated Thursday, December 14th. The stock was acquired at an average cost of $20.76 per share, with a total value of $191,303.40. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 36,153 shares of company stock valued at $731,583. 4.03% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Xencor (XNCR) Share Price” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2018/02/10/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-xencor-xncr-share-price.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply